Cosentyx
Phase 1Small molecule
Johnson & JohnsonCosentyx is one of 6 small molecule programs targeting Pityriasis Rubra Pilaris. It is currently in Phase 1.
1
Indications
5
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Pityriasis Rubra Pilaris
#DrugCompanyPhaseTrials
1Amevive
AstellasApproved
Taltz
Eli LillyPhase 2
Tremfya
Johnson & JohnsonPhase 2
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Cosentyx
NovartisPhase 1
Cosentyx
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
ART2 trials
Pityriasis Rubra Pilaris1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cosentyx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company